This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
No specific design criteria were identified by the authors for inclusion but the date range was 1980-1996. 
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Numerous studies were included.
Methods of combining primary studies
The sensitivity and specificity of PET and biopsy were determined by pooling data from 4 studies and 6 studies respectively. The remaining parameters used within the model were determined by selectingfrom the range identified within the review.
Investigation of differences between primary studies
Results of the review
The sensitivity and specificity of CT was 0.999 and 0.610, of PET was 0.925 and 0.83 and of biopsy was 0.895 and 0.959. The morbidity associated with surgery and biopsy was assessed to be 0.08 and 0.0008 years respectively. The mortality rate associated with exploratory surgery was 0.5% and that associated with curative surgery was 4%. The mortality rate associated with biopsy was either 0.2% or 2.5% depending upon the method used. The probability of malignancy was 0.83; the probability of resectable solitary pulmonary nodules was 0.8; the probability of pneumothorax as a result of biopsy was either 0.24 or 1 and the probability of an indeterminate biopsy was either 0.02 or 0.06 depending upon the method used.
Measure of benefits used in the economic analysis
The measure of benefits was life years gained derived from the decision model.
Direct costs
The costs associated with the diagnostic and subsequent clinical procedures were included within the analysis, including chest radiograph, thoracic computed tomography, thoracic positron emission tomography, transthoracic needle aspiration biopsy, video-assisted thoracoscopy, surgery and chest tubes. The costs were given per item and the resource use was determined by the model, although not specifically detailed within the paper. The quantity/cost boundary adopted was that of the health care provider. The costs are assumed to refer to 1995 (although this was not explicitly stated within the paper) and were not discounted.
Other issues
The authors relied on published data from the literature which has inherent biases. The data are often from specialised medical settings and are not externally valid a limitation acknowledged by the authors. The issue of generalisability to other settings and countries has not been addressed. The authors undertook an external check on the results of the model through comparison with a previously published model, although no other studies were identified for comparison. The authors correctly undertook the modelling at a population level and for mathematical simplicity split the population according to disease status (benign or malignant). Given that disease status is initially unobserved these patient groups must be treated identically within the decision tree until such time as the status is observed. Within the wait and watch strategy the observation period over which growth is determined is different for the two groups. It might have been better to use a Markov process to model the dynamic nature of the growth process.
The authors presented a simplified version of the decision tree within the paper which, whilst aiding comprehension, does suggest some structural problems within the model. Embedded decision nodes (those that occur downstream of the initial decision) are valid within clinical decision analysis where the aim is to maximise or minimise a value. However, the cost-effectiveness ratio employed within economic evaluation and the lack of a simple maximise or minimise decision rule means that embedded decision nodes can cause difficulties within models for economic evaluation. The authors stated a decision rule ($50,000 per life year saved) but it is unclear if this has been used to evaluate options at this embedded decision node. The results would have been clearer if the embedded decision nodes had been removed by incorporating separate strategies for each of the options (e.g. CT + PET with biopsy if the PET is negative and a separate strategy for CT + PET with wait and watch if the PET is negative).
The model also employs chance nodes where decision nodes are more appropriate and hence separate strategies should have been employed (e.g. after a positive CT there is a 20% chance of biopsy and a 80% chance of surgery). When a model is to be used to provide policy and practice guidanceit is inappropriate to employ chance nodes in this manner with probabilities determined according to current practice. Whilst this type of analysis provides an estimate of the costeffectiveness of current practice it fails to provide an estimate of the cost-effectiveness of optimal practice which would involve either biopsy or surgery but not a mixture of both. More specifically the decision tree suggests that the biopsy strategyis not associated with death if undertaken after a negative PET whilst there is a possibility of death when biopsy is used after a positive PET or straight after a positive CT. Some of these issues perhaps arise from the presentationof a simplified version of the decision tree within the paper.
Finally, theauthors have not calculated the incremental cost-effectiveness rations (ICERs) correctly. They have compared the costs and effects of each strategy with a base strategy as opposed to comparing each consecutively more expensive strategy to the next cheapest non-dominated strategy. The authors have not correctly identified dominated strategies that provide fewer life year gains at higher cost than other strategies. As such the ICERs presented within table 3 are misleading, although the graphs appear to provide an appropriate assessment of cost-effectiveness, and care should be taken when using the results of this analysis. For example within the base case the cost per life year for CT + PET is given as $4,273 compared with wait and watch. The correct approach would be to compare CT + PET with CT alone and to identify that the CT + PET strategy is dominated by CT only for the base case patient group.
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